Oncology
By Emily Bell
Navy Veteran Matthew Roach rang the celebration bell at the Lubbock VA Clinic on July 8, 2025, signifying his official triumph over terminal stage IV metastatic prostate cancer 1 year after being diagnosed. Read More ›
Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer with rising incidence globally. Read More ›
Pembrolizumab (Keytruda; Merck) has received an FDA nod for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 combined positive score (CPS) ≥1, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent. Read More ›
The Department of Veterans Affairs (VA) has been able to “dramatically increase” clinical trial opportunities and participation in recent years, thanks in large part to a joint initiative from the Prostate Cancer Foundation (PCF) and VA, according to data presented at the 2025 ASCO Annual Meeting, held in Chicago, IL, May 30-June 3, 2025, and published simultaneously online. Read More ›
Dr. Enrique Velazquez Villarreal, Assistant Professor in Department of Integrative Translational Sciences at City of Hope, discusses how his innovative AI tool, AI-HOPE, is revolutionizing cancer care by combining clinical data, genomics, and social determinants of health to enhance personalized treatments and patient outcomes. Read More ›
In Part 2 of our interview with Maimah Karmo we dive deeper into her advocacy work addressing health disparities in breast cancer care. Discover how Tigerlily is driving change through initiatives that empower underrepresented communities and advance equity in cancer outcomes. Read More ›
Join Maimah Karmo, founder and CEO of the Tigerlily Foundation and 20-year triple-negative breast cancer survivor, as she shares her inspiring journey of resilience and highlights Tigerlily’s transformative programs to empower women in the fight against breast cancer. Read More ›
Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer (NSCLC) may vary depending on demographic and sociological patterns, according to a study presented at the 2025 ASCO Annual Meeting, held in Chicago, Illinois, from May 30 to June 3, and published simultaneously online. Read More ›
A study that was published recently online analyzed data from more than 5000 US veterans with metastatic prostate cancer who underwent next-generation sequencing between 2019 and 2023 concluded that while non-Hispanic Black veterans had higher rates of actionable immunotherapy targets, non-Hispanic White veterans had more frequent alterations in androgen receptor signaling and DNA repair pathways. Read More ›
Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer (NSCLC) may vary depending on demographic and sociological patterns, according to a study presented at the 2025 ASCO Annual Meeting. Read More ›